Teleflex lands FDA clearance for Nylus vascular access catheter

Thu, 11/15/2012 - 3:53pm
Mass Device

The FDA clears Teleflex subsidiary Semprus BioScience's Nylus peripherally inserted central catheter, featuring proprietary Semprus Sustain technology.

Teleflex logo

Limerick, Pa.-based surgical device maker Teleflex's (NYSE:TFX) Semprus BioSciences subsidiary won FDA 510(k) clearance for its Nylus peripherally inserted central catheter, featuring the proprietary Semprus Sustain platform technology.

The newly approved device provides peripheral access to the central venous system for infusion, intravenous therapy, blood sampling, central venous pressure monitoring and power injection of contrast media, according to the press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.